SFU Library Licensed Material

Access to the content in this collection is restricted to current SFU faculty, students, and staff.

This collection contains various types of content licensed by the SFU Library on behalf of the University. 

Copyright and Terms of use

This work is protected by copyright in Canada unless its copyright has expired. The user is responsible for doing their own assessment. 

You may use this work as permitted by applicable licenses, fair dealing and other exceptions under copyright legislation in your jurisdiction. For guidance on seeking further permissions, contact the source/owner of the material.

Search within Collection

Displaying 1 - 15 of 710

18

sfulibr_60-Thumbnail Image.png
Date: 2013
Name(s): Chambers, Rich
Description: William Bur is an 18 year old senior in high school who for the first time in his life faces, but does not recognize, one of life's ultimate questions--what's next? The recognition comes from the adult William Bur, who narrates and comments throughout. It is the adult Bur that celebrates the idea of the "moment," even if the teenaged Bur is too busy with his 18 year old self to see it. Instead, caught somewhere between the 17 year old child and the 19 year old adult, the 18 year old Bur finds…

50 Years of Text Games: From Oregon Trail to A.I. Dungeon

50YearsOfTextGames-Thumbnail Image.png
Date: 2023-03-01
Name(s): Reed, Aaron A.

A long way to go

sfulibr_1385-Thumbnail Image.png
Date: 2017

Accelerating Lead Generation, Datamonitor report

BI00020-021-Thumbnail Image.png
Date: 2009-06-01
Name(s): Barton, Cheryl L.
Description: The number of approvals for new drugs has fallen steadilyin recent years, despite increasing R&D expenditure. Improvements in lead generation essential for companies aiming to avoid expensive compound failures in the later stages of development.

Advances in Alzheimer's Disease Drug Discovery,Datamonitor report

BI00040-005-Thumbnail Image.png
Date: 2011-05-26
Name(s): Templeton, David
Description: It is estimated that 115 million people globally will have Alzheimer's disease by 2050. In the US alone, a cost of $1,000bn is predicted. Disease-modifying therapies that delay the onset of AD or slow its progression are a major unmet medical need.

Advances in Drug-Diagnostic Co-Development,Datamonitor report

BI00041-002-Thumbnail Image.png
Date: 2011-05-05
Name(s): Barton, Cheryl L., Sleigh, Sara
Description: To successfully market a targeted drug it is essential to have an associated diagnostic test to identify the correct patients. As more targeted drugs are developed drug-diagnostic co-development is of increasing importance to pharma market growth.